Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Toshimichi Asano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6832-9385; OpenAlex author ID A5101660111. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
94
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 15

  1. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  4. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  5. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study. Co-author DOI 10.1016/j.eclinm.2024.102936↗
  6. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  7. A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1016/j.pdpdt.2020.102157↗
  8. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001665↗
  9. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. Co-author DOI 10.1158/1535-7163.mct-19-0491↗
  10. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery? First author DOI 10.1007/s11605-018-3972-x↗
  11. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14023↗
  12. [Ⅲ.Management of Biliary Drainage in Patients Undergoing Neo-Adjuvant Therapy for Biliary or Pancreatic Cancer]. Co-author PMID 31631131↗
  13. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. Co-author DOI 10.1002/jhbp.565↗
  14. Oncological emergency surgery for metachronous large and small bowel metastases after pancreaticoduodenectomy for pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-018-0506-4↗
  15. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal aden… Co-author DOI 10.1007/s00595-016-1420-7↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Hirano · 14 shared papers, 2017–2026 · strength 1.59
  2. Yoshitsugu Nakanishi · 10 shared papers, 2017–2022 · strength 0.87
  3. Takahiro Tsuchikawa · 10 shared papers, 2017–2022 · strength 0.87
  4. Toru Nakamura · 10 shared papers, 2017–2022 · strength 0.87
  5. Toshiaki Shichinohe · 9 shared papers, 2017–2022 · strength 0.77
  6. Yosuke Inoue · 3 shared papers, 2025–2026 · strength 0.55
  7. Sohei Satoi · 3 shared papers, 2025–2026 · strength 0.55
  8. Masamichi Mizuma · 3 shared papers, 2025–2026 · strength 0.55
  9. Daisuke Hashimoto · 3 shared papers, 2025–2026 · strength 0.55
  10. Michiaki Unno · 3 shared papers, 2025–2026 · strength 0.55
  11. Kenjiro Okada · 2 shared papers, 2026 · strength 0.39
  12. Kenichiro Uemura · 2 shared papers, 2026 · strength 0.39
  13. So Yamaki · 2 shared papers, 2025–2026 · strength 0.37
  14. Atsushi Oba · 2 shared papers, 2025–2026 · strength 0.37
  15. Fuyuhiko Motoi · 2 shared papers, 2025–2026 · strength 0.37
  16. Atsushi Masamune · 2 shared papers, 2026 · strength 0.36
  17. Ippei Matsumoto · 2 shared papers, 2025–2026 · strength 0.35
  18. Tsutomu Fujii · 2 shared papers, 2025–2026 · strength 0.35
  19. Kyoko Hida · 2 shared papers, 2020–2024 · strength 0.24
  20. Denys Tsybulskyi · 1 shared paper, 2026 · strength 0.20
  21. Teiichi Sugiura · 1 shared paper, 2026 · strength 0.20
  22. Shoki Sato · 1 shared paper, 2026 · strength 0.20
  23. Ryuta Shintakuya · 1 shared paper, 2026 · strength 0.20
  24. Daisuke Ban · 1 shared paper, 2026 · strength 0.20
  25. Katsuhisa Ohgi · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.